HIV-1 viral protein R (Vpr) is predominantly localized to the nucleus and plays an important role for viral preintegration complex import into the nucleus. In this study, we investigated the influence on subcellular localization of Arg residues in the C-terminus of Vpr. Consistent with previous studies, about 90% of the cells manifested diffuse nuclear staining in the Vpr-expressed cells. Besides diffuse nuclear staining, punctate perinuclear staining, and punctate cytoplasmic staining were also observed in the immunofluorescence studies. Deletion of the Ser-Arg-Ile-Gly residues (amino acids 79±82; SRIG) had no effect on the Vpr localization. However, deletion of the Arg-Gln-Arg-Arg residues (amino acids 85±88; RQRR) resulted in a smooth perinuclear staining pattern. Substitution of five Arg residues with Asn (amino acids 80, 85, 87, 88, and 90; R 3 N5) resulted in a diffuse cytoplasmic staining. Subcellular fractionation analyses support the immunofluorescence staining results. These findings indicate that the C-terminal Arg residues of HIV-1 Vpr play an important role for Vpr nuclear localization. All the Vpr mutants were appropriately expressed, exhibited no significant defect on the protein stability, and were incorporated efficiently into virus-like particles. Both SRIG and R 3 N5 mutants lost their cell cycle arrest activities and the RQRR deletion only exhibited a low level of cell arrest activity. Therefore, the Arg residues in the HIV-1 Vpr C-terminus are important for Vpr nuclear localization and cell cycle arrest , but had no effect on protein stability or Vpr incorporation into virus-like particles.
INTRODUCTION
In addition to the basic functions encoded by gag, pol, and env, the human immunodeficiency virus type 1 (HIV-1) genome includes at least six additional genes (tat, rev, vpr, vpu, vif, and nef) with distinct regulatory roles (Cullen and Green, 1990; Subbramanian and Cohen, 1994) . HIV-1 vpr encodes a protein [viral protein R (Vpr)] of 96 amino acids (Wong-Staal et al., 1987) . The role of Vpr in virus replication in vitro is cell type dependent. Vpr is dispensable for replication of HIV and SIV in transformed monocytoid and T cell lines (Dedera et al., 1989; Ogawa et al., 1989) , but expression of vpr products is essential for virus replication in primary macrophages (Balliet et al., 1994; Campbell and Hirsch, 1997; Cohen et al., 1990; Dedera et al., 1989; Fletcher et al., 1996; Nishino et al., 1991) . The role of Vpr in HIV pathogenesis is still not clear. It was reported that SIV mac Vpr is important for the development of an AIDS-like disease in rhesus macaques (Lang et al., 1993) . However, other studies have resulted in ambiguous results (Gibbs et al., 1995; Hoch et al., 1995) . Although there are no conserved vpr mutations in long-term survivors, a mother and child pair study has shown that a correlation between disease progression and vpr gene mutations, especially mutations in the 3Ј-end of vpr gene (Wang et al., 1996) . Furthermore, risk group-associated differences in HIV-1 Vpr sequences are also located in the C-terminal region (Kuiken et al., 1996) . Another Vpr function, which may be related to HIV pathogenesis, is its ability to increase the mutation rate about fourfold (Mansky, 1996) . Therefore, Vpr could be an important factor for HIV-1 diversity, which increases the chance for the virus to escape immune system or drug attack. Therefore, the Vpr product, especially the C-terminal region of Vpr, could play an important role in HIV pathogenesis and AIDS development. Levy et al. first have shown that Vpr expression in rhabdomyosarcoma cells prevented cell proliferation and induced differentiation (Levy et al., 1993) . Other groups have also observed that, in vitro, Vpr prevents the establishment of chronically infected HIV-1 producer cell lines, suggesting that cell cycle arrest could be one of the important roles for Vpr in HIV-1 replication (Rogel et al., 1995) . It has been suggested that the ability of Vpr to block cell division is by blocking the mitotic cell cycle in the G2 phase (Di Marzio et al., 1995; Emerman, 1996; Mahalingam et al., 1995c; Re et al., 1995; Rogel et al., 1995) . Vpr-induced cell cycle arrest in the G2 phase is conserved from yeast (Zhang et al., 1997; Zhao et al., 1996) to primate lentiviruses (Planelles et al., 1996; Stivahtis et al., 1997) .
One of the most important characteristics of Vpr is its ability to facilitate transport of the viral preintegration complex into the nucleus of nondividing cells in conjunction with a nuclear localization sequence present in the Gag MA protein (MA-NLS) (Heinzinger et al., 1994) . Vpr facilitates replication in primary macrophages, consistent with the presence of Vpr in virions and its localization in the nucleus of transfected cells (Balotta et al., 1993; Connor et al., 1995; Hattori et al., 1990; Westervelt et al., 1991) . As the result, Vpr is required for replication in macrophages, which do not divide, but is dispensable in dividing cells, such as activated peripheral blood mononuclear cells (Connor et al., 1995) .
Since our first report on the nuclear localization of Vpr (Lu et al., 1993) , several investigators have confirmed that Vpr is a nuclear protein (Mahalingam et al., 1995a; Yao et al., 1995; Zhao et al., 1994b) . It has been suggested that the karyopherin pathway is not involved in Vpr nuclear localization or that the interaction of Vpr with another protein with a NLS accounts for Vpr import into the nucleus (Gallay et al., 1996) . Recently, the direct interaction of Vpr with karyopherin-␣ has been demonstrated (Popov et al., 1997) . However, a typical NLS sequence from SV40 large T antigen could not block Vpr binding with karyopherin-␣ although it did block MA association with karyopherin-␣, suggesting that the Vpr binding site(s) on karyopherin-␣ is different from that of MA. Sequence analysis showed that the C-terminus of Vpr is highly basic, a common feature of NLS. Removal of amino acids 78±96, which contain the basic residues region, greatly impaired Vpr nuclear localization (Lu et al., 1993) . However, Zhao et al. reported that deletion of either amino acids 88±96 or amino acids 78±87 did not affect nuclear localization of Vpr (Zhao et al., 1994a) . Furthermore, the mutagenic analyses by both groups have demonstrated an important role in nuclear localization for the ␣-helix near the N-terminus, although no NLS-like sequence is present in that region (Mahalingam et al., 1995b; Yao et al., 1995) .
In this study, the roles of the carboxyl-terminal arginine-rich sequence of Vpr in cellular localization, cell cycle effects, and the Vpr export and incorporation into virus particles were specifically studied. Our data suggested that the arginine residues in the C-terminal region are important for Vpr localization and cell arrest, but have no significant effect on Vpr incorporation into virus-like particles.
RESULT Vpr C-terminal mutations
Our previous results have shown that the C-terminal region of HIV-1 Vpr is important for the Vpr nuclear localization. For further investigation of Vpr nuclear targeting, we have generated deletion and substitution mutants of the basic domain of Vpr (Fig. 1) . This region contains five to seven Arg residues, depending on the HIV-1 isolate. Five Arg residues, found at positions 80, 87, 88, 90, and 95, are highly conserved among HIV-1 isolates, whereas Arg residues at positions 77 and 85 are less well conserved and are substituted with Gln in about 50% of strains. To analyze the role of these Arg residues in Vpr localization and cell cycle arrest functions, three mutants were generated. The first one is a deletion mutant of Ser-Arg-Ile-Gly at residues 79±82 (SRIG) and designated as pTM-VPR SRIG . Another mutant is a deletion of Arg-Gln-Arg-Arg at residues 85±88, designated as pTM-VPR RQRR (Fig. 1) . The third mutant is a substitution mutant in which five of the Arg codons (positions 80, 85, 87, 88, and 90) are substituted with Asn codons and is designated as pTM-VPR R3N5 (Fig. 1) .
Stability of Vpr
The stability of HIV-2 Vpr protein was shown to be important for its cell cycle arrest activity (Kewalramani et al., 1996) . Although some studies suggested that the protein expression level is not critical for Vpr cell cycle arrest function, other studies in the yeast system have suggested that the protein expression level does affect the cell growth (Macreadie et al., 1995) . To compare the expression and stability of wild-type Vpr with that of the mutant proteins, 293-tet-induced cells were transfected with pUHD-Vpr and its relevant mutants for 24 h. The cells were then metabolically labeled with 100 Ci/ml of [4,5- 3 H]leucine for 12 h and chased in the absence of radioisotope for 30 min. The cells were harvested at different time points and immunoprecipitations were carried out ( Fig. 2A) . The proportion of Vpr protein or mutant protein at different time points was determined by laser densitometry. Wild-type Vpr and the mutant proteins were expressed at similar levels ( Fig. 2A) . It is interesting that the half-lives of Vpr SRIG and Vpr RQRR were about 20 h while the half-life for the wild-type Vpr protein was only about 11 h (Fig. 2B) . Vpr R3N5 was a less stable protein with a half-life of 7 h, similar to that of wild-type Vpr (Fig.   FIG. 1 . The C-terminal sequence of wild-type and mutant Vpr proteins. The C-terminal sequence from pNL4-3 Vpr used in this study is shown on the top. The other sequences are those for the deletion and substitution mutants. LR, leucine-rich domain. 2B). Thus, all the mutant are expressed well and are relatively stable in the cells.
Influence on Vpr localization of mutations of Cterminal basic sequences
To study cellular localization, Vpr or its relevant mutant gene products were expressed in the Hela cells using the vaccinia virus expression system, stained with antiVpr antiserum and a secondary fluorescein isothyocyanate (FITC)-conjugated antibody, and examined by confocal microscopy. Intensive immunofluorescence was observed in cells transfected with Vpr constructs (Figs. 3A±3D), but no fluorescence was observed in cells transfected with vector alone (Fig. 3E ). Similar to our previous findings (Lu et al., 1993) , the wild-type Vpr and Vpr SRIG displayed a variety of staining patterns, including diffuse nuclear (Fig. 3A) , punctate perinuclear (Fig. 3B) , and punctate cytosolic staining. Most of the cells exhibited more than one staining pattern, which were quantitated from 50 randomly selected positive cells. Sixty-six percent of the cells had strong diffuse nuclear staining, whereas 24% exhibited weaker nuclear staining. Seventy-two percent of the cells had punctate perinuclear staining, and 86% of the cells showed punctate cytosolic staining.
Vpr SRIG showed no significant difference from wildtype Vpr in the immunofluorescence staining pattern (data not shown). In contrast to the variable staining pattern of wild-type Vpr or Vpr SRIG , almost all of the Vpr RQRR -transfected cells displayed smooth perinuclear staining (Fig. 3C ). Weak diffuse nuclear staining was present in a small proportion of these cells. The Vpr R3N5 -transfected cells displayed exclusively diffuse cytosolic staining (Fig. 3D) , distinct from the cytosolic staining pattern of wild-type Vpr which was more condensed. These results indicate that the Arg residues in the Cterminus of Vpr influenced the protein's localization.
Subcellular fractionation
In the immunofluorescence staining analysis, HIV-1 Vpr and its mutant proteins showed several distinct staining patterns, including diffuse nuclear staining, perinuclear staining, and cytoplasmic staining. To confirm our immunostaining results and study whether the Vpr protein may be associated with distinct cellular compartments, subcellular fractionation was carried out. Vpr or its relevant mutant gene products were expressed in the Hela cells using the vaccinia virus expressing system. The infected/transfected cells were labeled for 16 h with [4, H]leucine, harvested, and fractionated into membrane, cytosol, nuclear wash, nucleoplasm, and chromatin and matrix as described under Material and Methods. No wild-type Vpr protein was found in the cytosolic fractions and the membrane fractions (Fig. 4A ). When the nuclear pellet was washed with the buffer containing Triton X-100, 13% of Vpr protein was detected in the nuclear wash fraction. When the pellet was washed further with the buffer containing NP-40, 36% of the Vpr was in the nucleoplasm fraction. However, the majority of the protein (51%) was located in the chromatin and nuclear matrix fraction (Fig. 4A) . These results are similar to our previous observations, indicating that the HIV-1 Vpr protein is mainly located in the nucleus and may be associated with some nuclear components (Lu et al., 1993) .
Deletion of the SRIG sequence did not affect the localization of the Vpr protein in the subcellular fractionation analysis. A similar ratio of the Vpr SRIG protein was found in each fraction compared to wild-type Vpr (Fig.  4A ). The proportion of the RQRR deletion mutant in each fraction was different, with more protein detected in nuclear wash (30%) and nucleoplasm (37%) fractions and less protein found in the chromatin/nuclear matrix (33%) fraction (Fig. 4A ). When all five of the Arg residues were changed to Asn, the majority of the protein (80%) was detected in the nuclear wash fraction and very little protein was detected in the nucleoplasm (10%) and almost no signal was found in the chromatin/nuclear matrix fraction (Fig. 4A) .
The vaccinia expression system has been widely used to express Vpr, but vaccinia-induced cytotoxicity could have affected the subcellular distribution. To avoid the vaccinia cytotoxicity effects, 293-tet-induced cells were transfected with pUHD-VPR, pUHD-VPR SRIG , pUHD-VPR RQRR , and pUHD-VPR R3N5 , respectively, and analyzed as described under Material and Methods. No wild-type Vpr protein was found in the cytosolic fractions and the membrane fractions. Eleven percent of Vpr protein was detected in the nucleoplasm fraction, while the majority of the protein (89%) was located in the chromatin and nuclear matrix fraction (Fig. 4B) . A similar ratio of the Vpr SRIG protein was found in each fraction compared to wild-type Vpr (Fig. 4B) . The proportion of the RQRR deletion mutant in each fraction was different, with more protein detected in nuclear wash (9%) and less protein found in the chromatin/nuclear matrix (60%) fraction (Fig.  4B) . Similar to the observations in the vaccinia expression system, the majority of Vpr R3N5 (90%) was detected in the nuclear wash fraction and very little protein was detected in the nucleoplasm and almost no signal was found in the chromatin/nuclear matrix fraction (Fig. 4B) .
Vpr and its relevant mutants have similar localization patterns in the both expression systems. Although the majority of the Vpr R3N5 is located outside of the nucleus, it is not in a soluble form in the cytoplasm, suggesting that the protein may be associated with a cellular structure, or compartment in the cytoplasm. To rule out contamination during the cell fractionation, bacterial ␤-galactosidase, characterized as a soluble protein in the cytosolic fraction, was coexpressed with Vpr or its mutant proteins in these assays. More than 90% of the ␤-galactosidase activity was found in the cytosol, as measured by enzymatic assay. Less than 5% of the ␤-galactosidase activity was detected in the postnuclear wash or membrane fractions, and no detectable activity was found in the purified nuclei (data not shown). Therefore, the Arg residues in the C-terminal region of the Vpr protein are important for localization.
Virion incorporation of Vpr mutants
To examine virion incorporation, the vaccinia virus expression system was used, since it has been shown to faithfully reproduce the properties of retrovirus assembly (Spearman et al., 1994) . Our previous report showed that expression of p55 gag alone resulted in the formation of virion-like particles with a density of 1.16±1.17 g/ml, similar to that of HIV-1 particles. Coexpression of Gag and Vpr resulted in the export of Vpr from transfected cells and incorporation into these virus-like particles (Lu et al., 1993) .
When Vpr and the mutants were coexpressed with p55 gag in BSC40 cells, no significant differences were noted in the level of expression of Vpr mutants compared to the wild-type protein (Fig. 5, lanes 1 to 4) . In the absence of Gag expression, none of the Vpr protein was exported to the medium (data not shown). In contrast, coexpression of Gag resulted in Vpr export in all cases (Fig. 5, lanes 5±8 ). Densitometric analysis indicated that the incorporation ratio of mutant Vpr protein was either similar to or slightly better than that of wild-type Vpr, suggesting that the mutants have no defect on Vpr incorporation into virus-like particles.
Cell cycle arrest analysis of Vpr and its mutant proteins
One of the functions of HIV-1 Vpr is to cause cell cycle arrest in G2/M phases, which has been suggested to relate to HIV pathogenesis. Therefore, we further explored whether mutations at the Arg residues would affect the Vpr cell cycle arrest function (Fig. 6) . pUC12, pcDNA-VPR, pcDNA-VPR SRIG , pcDNA-VPR RQRR , and pcDNA-VPR R3N5 were transfected into 293 cells, and the cell cycle effect was analyzed by propidium iodide staining. In the previous reports, Vpr was shown to cause the cell cycle arrest in the G2/M phase of 293 cells. In support of this, our results showed that about 75% of Vpr expressing cells were in the G2/M phase (Fig. 6B) ; in contrast to pUC12-transfected cells, the negative control, had about 20% of the cells in the G2/M phase (Fig. 6A) (Di Marzio et al., 1995) . It has been reported that the H(F/ S)RIG sequences are important for cell cycle arrest in yeast and further confirmed its importance in mammalian cell expression systems using synthetic peptides (Macreadie et al., 1995 (Macreadie et al., , 1996 . However, there are no data with full-length Vpr protein that supports this conjecture in the mammalian cells. Our results indicated that deletion of SRIG abolished Vpr cell cycle arrest, suggesting that the SRIG sequence is important for cell cycle arrest (Fig. 6C) . When the pcDNA-VPR RQRR was transfected into 293 cells, a partial effect on cell cycle was observed which was about 20% of the activity of that of wild-type Vpr (Fig. 6D) . The pcDNA-VPR R3N5 showed no cell cycle arrest (Fig. 6E) . These results suggest that the Arg residues in the C-terminus are important for Vpr cell cycle arrest.
DISCUSSION
Although deletion of the entire C-terminal region of Vpr resulted in a protein with reduced stability (Lu et al., 1993; Mahalingam et al., 1995a; Paxton et al., 1993; Yao et al., 1995) , the more restricted mutations used in this study had no apparent effect on Vpr expression, stability, or virus-like particle incorporation. In contrast, mutation in the N-terminal ␣-helix, which disrupted Vpr localization in the nucleus, also disrupted virion incorporation, suggesting that these mutations could have global effects on protein folding (Mahalingam et al., 1995a; Yao et al., 1995) . Our results correspond with previous observations that the C-terminal sequence is dispensable for virion packaging (Lu et al., 1993; Mahalingam et al., 1995a; Paxton et al., 1993; Yao et al., 1995) . No significant packaging defect was observed with the three Vpr mutants described in this study in spite of their different nuclear localization patterns, suggesting that the nuclear localization of Vpr protein is not related to Vpr packaging.
Our previous report documented that Vpr is predominantly localized in the nucleus (Lu et al., 1993) . In addition, a small portion of Vpr was localized in a different cellular compartment. In this study, we demonstrated that wild-type Vpr has several staining patterns revealed by confocal microscopy, including diffuse nuclear, punctate perinuclear, and punctate cytoplasmic staining. The ability of Vpr to localize to several cellular compartments may explain its ability to mediate various biological activities, including the ability to target the viral preintegration complex to the nucleus, arrest the cell cycle in the G2 phase, and its ability to act as an ion channel (Piller et al., 1996) .
The Vpr C-terminal sequence plays a role in Vpr nuclear localization, since Vpr with a C-terminal deletion of residues 76±96 is located in the cytoplasm (Lu et al., 1993) . Recently, the N-terminal ␣-helix has been reported to be important for Vpr nuclear localization (Mahalingam et al., 1995a) . The Vpr SRIG mutant had a similar localization in both the immunofluorescence and the cellular fractionation experiments to that of wild-type Vpr. However, the Vpr RQRR protein localization was changed. Most of the protein was detected in the perinuclear region by immunofluorescence staining and cellular fractionation. About half of the protein was detected in the nuclear wash or nucleoplasm fractions. The immunofluorescence experiments were performed at 4 h postinfection to minimize the vaccinia cytopathic effects, while the fractionation experiments were done after 16 h of labeling the transiently expressing cells. Therefore, the immunofluorescence results are representative of highly expressed Vpr protein at an early stage of expression, while the transient expression of Vpr in either HeLa cells using vaccinia expression system or in the 293-tet-induced cells was representative of stable Vpr protein in these cells. The RQRR deletion Vpr may only partially affect localization. As a result, more Vpr RQRR protein is located in the perinuclear region and less protein was found in the chromatin/matrix fractions. Substitution of Arg at amino acids 80, 85, 87, 88, and 90 with Asn residues impaired nuclear localization, further indicating that the Arg residues are important for Vpr localization. Although the Vpr R3N5 protein was detected in the cytoplasm in the immunofluorescence studies, the protein is not free in the cytoplasm because the majority of the protein is found in the nuclear wash fraction, suggesting that most of the protein is either in, or associated with, cellular components. Therefore, to study the Vpr localization, especially the protein located in the cytoplasm, a cellular fractionation assay should be performed. Previous attempts to identify the nuclear localization signal from Vpr have not been successful. For example, the C-terminal basic region of Vpr fused with ␤-galactosidase could not drive majority of fusion protein into the nucleus, like a typical NLS, but did change the fusion protein cellular localization, and more LacZ activity was detected in the nuclear fraction (including nuclear wash, nucleoplasm, and chromatin and matrix) compared to the cytosol fraction, suggesting that the C-terminal region of Vpr could regulate protein localization (data not shown). This result provides further support to the contention that the C-terminal of Vpr is important for protein localization.
In vitro, Vpr causes cell cycle arrest in the G2 phase (Di Marzio et al., 1995; He et al., 1995; Jowett et al., 1995; McCarthy, 1995; Planelles et al., 1996; Re et al., 1995; Stivahtis et al., 1997; Zhao et al., 1996) . Since the Cterminal truncated Vpr could not cause cell cycle arrest (Di Marxio et al., 1995) , this suggests that the C-terminal region of the Vpr protein is necessary for this activity. More detailed studies have shown that the H(F/S)RIG sequences in the C-terminal region are critical for cell cycle arrest, and peptides which contain these sequences could arrest cells, suggesting that the H(F/ S)RIG sequence is sufficient for cell cycle arrest function (Macreadie et al., 1996; Macreadie et al., 1995; Zhang et al., 1997) . Single Arg residue mutations at position 80 abolished Vpr cell cycle arrest function, suggesting that this residue also plays an important role in the cell cycle arrest (Di Marzio et al., 1995) . Vpr SRIG could not arrest the cell cycle although the localization and virion incorporation abilities of this protein were similar to wild-type Vpr. This result further suggests that the SRIG sequence is one of the cell cycle arrest functional domains. It is very interesting that less of the RQRR mutant protein is in the nucleus than wild-type Vpr, and this mutant only partially affects cell cycle arrest. In contrast, the Vpr R3N5 protein was located outside of the nucleus and had no cell cycle arrest activity. It is not clear whether this defect is due to the protein localization change. It has been suggested that the interaction of Vpr with cellular proteins may be related to Vpr cell cycle arrest (Planelles et al., 1996; Selig et al., 1997; Stivahtis et al., 1997) . The cellular localization changes of the mutant Vpr proteins may affect their interactions and in turn affect the cell cycle arrest activity of this protein.
MATERIALS AND METHODS

DNA constructs
The vpr gene of HIV-1 NL4-3 was cloned into pTM-3 to generate pTM-VPR, as previously described (Lu et al., 1993) . To analyze the role of these Arg residues in Vpr localization, three mutants were generated. The first one is a deletion mutant of codons 81±84 (Ser-Arg-Ile-Gly), designated as pTM-VPR SRIG (Fig. 1) . This was done by inserting the oligonucleotides 5Ј-TCGAC ATG TTACT CGA CAGAGGAGA GCGCG CAAT-3Ј and 5Ј-TCGAC TAAGA TCTAC TGGCT CCATTG CGCGC TCTCCTCTG TCG AGTAA CAT G-3Ј at the unique SalI site at position 5785. HIV-1 nucleotides 5558±5869, encompassing the mutant vpr gene were obtained by PCR using primers 5Ј-AATAC CATGG AACAA GCCCC CCAGA AGA-3Ј and 5Ј-GATGC TTCCA GGGAT CCGTC TAGGA TCTAC TG-3Ј. The reaction product was digested with NcoI and BamHI and cloned into pTM-3. The second mutant is a deletion mutant of codons 85±88 (Arg-Gln-Arg-Arg), designated as pTM-VPR RQRR (Fig. 1) . This was done by inserting the oligonucleotides 5Ј-TCGAC ATAGC AGAAT AGGCG TTACT GCGCG CAAT-3Ј and 5Ј-TCGAC TAAGA TCTAC TGGCT CCATTG CGCGC AGTAA CGCCT ATTCT GCTAT G-3Ј at the unique SalI site at position 5785 located in the 3Ј end of the vpr open reading frame, corresponding to amino acid residue 76. HIV-1 nucleotides 5558±5869, encompassing the mutant vpr gene were obtained by PCR using primers 5Ј-AATAC CATGG AACAA GCCCC CCAGA AGA-3Ј and 5Ј-GATGC TTCCA GGGAT CCGTC TAGGA TCTAC TG-3Ј. The reaction product was digested with NcoI and BamHI and cloned into pTM-3. The third mutant is a substitution mutant in which five of the Arg codons (positions 80, 85, 87, 88, and 90) were substituted with Asn codons and is designated as pTM-VPR R3N5 (Fig. 1) . This was constructed by ligation of the following four oligonucleotides into the proviral clone at the SalI site: 5Ј-TCGAC ATAGC AACAT AGGCG TTACT AACCA G-3Ј, 5Ј-TGTTC TGGTT AGTAA CGCCT ATGTT GCTAT G-3Ј, 5Ј-AACAA CGCAA ACAAT GGAGC CAGTA GATCT TAG-3Ј, and 5Ј-TCGAC TAAGA TCTAC TGGCT CCATT GTTTG CGT-3Ј. The resultant mutated vpr gene was cloned into pTM as described above.
The pcDNA-VPR, -VPR RQRR , -VPR R3N5 , and -VPR SRIG were constructed by ligation of the NcoI/BamHI fragments from pTM-VPR, pTM-VPR RQRR , pTM-VPR R3N5 and pTM-VPR SRIG into HindIII/BamHI sites of pcDNA3.1 (Invitrogen) after blunted HindIII and NcoI sites with Klenow DNA polymerase I.
To construct the tet-induced plasmids, pTM-VPR and its relevant mutant plasmids were digested with NcoI, treated with Klenow DNA polymerase I, and then digested with BamHI. The purified DNA fragments were cloned between the EcoRI and BamHI sites of pUHD-10-3 (kindly provided by Dr. H. Bujard; Gossen and Bujard, 1992) after blunting the EcoRI site with Klenow DNA polymerase I to obtain pUHD-VPR, pUHD-VPR SRIG , pUHD-VPR RQRR , and pUHD-VPR R3N5 .
All the plasmids were confirmed by DNA sequence using the Sequenase Version 2.0 DNA sequencing kit (USB) based on the dideoxynucleotide termination method (Sanger et al., 1977) . The sequence analyses were carried out with the DNA Striker program.
Cell lines and culture
293, BSC40, and HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum, 100 U of penicillin/ streptomycin per milliliter. 293-tet-induced cell lines were obtained by transfecting pUHD-17-3, which encodes the reverse Tet-responsive transcriptional activator (kindly provided by Dr. H. Bujard; Gossen and Bujard, 1992) into 293 cells and the highly inducible clones were selected as described elsewhere (Gossen and Bujard, 1992) . The cell lines were maintained in DMEM supplemented with 10% heat-inactivated tetracycline-free fetal calf serum (Clontech), 100 U of penicillin/ml, 100 g of streptomycin/ml, and 200 g/ml of G418. To induce gene expression, 2 g/ml of doxycycline (Sigma) was added.
DNA transfection
Cells were grown to 80% confluence on 60-mm-diameter culture dishes and transfected with lipofectamine as recommended by Gibco-BRL. Briefly, solution A was prepared by adding 3 g plasmid DNA into 150 l of Opti-MEM I reduced-serum medium (Gibco-BRL) and solution B by adding 9 l of lipofectamine into 150 l of Opti-MEM I reduced-serum medium. Solution A and B were mixed gently and left for 15±30 min at room temperature. Meanwhile, 1.2 ml of Opti-MEM I reduced-serum medium was added to plates after washing two times with serum-free medium. The AϩB mixture was then added to the plate. After incubation for 4 h or overnight, 1.5 ml DMEM containing 20% fetal calf serum (FCS) was added. After 5 h incubation, the medium was replaced with DMEM with 10% FCS and antibiotics. The transfected cells were either analyzed at 48 to 72 h after transfection or selected with G418 to generate stable cell lines.
Subcellular fractionation
Infection±transfection protocol for the vaccinia virus expression system was as described elsewhere (Fuerst et al., 1986) . Briefly, Hela cells were grown to 90% confluence on 60-mm-diameter plates, infected for 1 h at 37°C with vTF7-3, a vaccinia virus expressing T7 RNA (Fuerst et al., 1986) at a multiplicity of infection (m.o.i.) of 10, and then cotransfected with pTM-VPR constructs and pTM-LacZ at the ratio of 20:1 by the lipofectamine transfection method. Four hours after transfection, the cells were labeled for 16 h with 1.5 ml of leucine-free DMEM containing 100 Ci of [4,5- 3 H]leucine per milliliter. The cells were then chased with DMEM with 10% FCS for 4 h. Labeled cells were fractionated into membrane, cytosolic, postnuclear, nucleoplasm, and chromatin and nuclear matrix fractions as previously described (Lu et al., 1993) . The purity of the nuclear fractions (nucleoplasm and chromatin and nuclear matrix) was examined by using a control cytosolic protein, ␤-galactosidase, expressed in the same cells from pTM-LacZ. To express Vpr in 293-tet-induced cells, the cells were transfected with pUHD-VPR, pUHD-VPR SRIG , pUHD-VPR RQRR , and pUHD-VPR R3N5 , respectively, and labeled with 100 Ci of [4,5- 3 H]leucine per milliliter for 16 h. The cells were then harvested, fractionated, and the amount of Vpr in each fraction determined as described above.
Immunoprecipitation
Equivalent proportions (v/v) of each of the subcellular fractions were mixed with an equal volume of 2ϫ SDS-PAGE sample buffer (0.125 M Tris±HCl, pH 6.8, 20% glycerol, 10% v/v 2-mercapoethanol, 4% w/v SDS) and boiled for 10 min. After spinning briefly, the sample was diluted 40-fold with RIPA buffer without SDS (1% v/v Triton X-100, 0.5% w/v deoxycholate, and 0.2 mM PMSF in PBS). An aliquot was taken for scintillation counting to determine relative labeled protein content. Immunoprecipitation was performed by the addition to equivalent proportions (v/v) of each of the subcellular fractions to 5 l of anti-Vpr antiserum. Incubation was continued overnight at 4°C. Twenty microliters of immobilized proteinA (50% v/v in PBS) beads (rproteinA, Repligen Co.) were added, and the mixture was incubated for 15 to 120 min at 4°C. Immunoprecipitates were collected at 500g for 30 s at room temperature and washed three times with RIPA buffer and once with PBS. The beads were resuspended in 30 l of SDS±PAGE sample buffer treated at 100°C for 10 min before loading onto 15% denatured polyacrylamide gel. The gels were infused with 1 M sodium salicylate for 45 min, dried on filter paper, and exposed to a XAR-5 film (Kodak) at Ϫ80°C with intensifying screens. Band intensities were determined by densitometry.
Immunofluorescence
To study the Vpr localization, Hela cells were seeded on glass coverslips (Nunc) at a density of 1 ϫ 10 5 cells per well in a 24-well plate and were infected for 60 min with vTF7-3. Then the pTM-VPR, pTM-VPR SRIG , pTM-VPR RQRR , pTM-VPR R3N5 , or pTM vector alone was transfected using lipofectamine. The cells were harvested 4 h after transfection and fixed with 2.5% (w/v) glutaraldehyde for 15 min in order to minimize the cytopathic effects caused by vaccinia virus infection. After permeabilizing the cells with 0.2% (v/v) Triton X-100 for 6 min at room temperature, the cells were then blocked for nonspecific binding of immunoglobulin by incubation for 30 min with PBS containing 5% (w/v) nonfat dry milk and 0.1% (v/v) Tween 20. Slides were then incubated with rabbit anti-Vpr antibody (1:100 in PBS with 0.5% Tween 20 and 1% bovine serum albumin) for 1 h at room temperature. The cells were washed several times with 0.3% (v/v) Triton X-100 in PBS and incubated at 4°C for 60 min with FITCconjugated goat anti-rabbit immunoglobulin G to detect Vpr. The slides were washed extensively with PBS and mounted in Aqua mount solution (Lerner Lab) containing 2.5% 1,4-diazobicyclo-[2,2,2]-octane (Sigma) to prevent photobleaching of the FITC signal. Slide preparations were examined on a Nikon fluorescence microscope equipped with appropriate filters and a microflex UFX camera system. Photographs were prepared by using Kodak T-MAX film, push processed to ASA 3200.
Particle incorporation
BSC40 cells were infected with vTF7-3 at a m.o.i. of 2 and cotransfected with the Vpr expression plasmids together with pTM-GAG, containing the entire p55 gag sequence from HXB2 (Lu et al., 1993) . Four hours after transfection, the cells were metabolically labeled for 20 h with 2 ml of leucine-free DMEM containing 10% dialyzed fetal calf serum and 100 Ci of [4, H]leucine/ml. The culture supernatants were removed and centrifuged at 2500 rpm for 15 min in a Beckman GS-6 rotor to remove cellular debris. Particles were concentrated by sedimentation through a 20% sucrose cushion prepared in PBS at 25,000 rpm for 90 min at 4°C in an SW28.1 rotor. Particles were resuspended in 2ϫ SDS±PAGE sample buffer as described above. The Gag and Vpr proteins in the supernatants or cell lysates were immunoprecipitated overnight at 4°C with both the anti-Gag and anti-Vpr antisera as described earlier.
Flow cytometry
293 cells were cotransfected with different pcDNA-VPR and its relevant mutants plasmids and pTK-hygromycin (5:1) by lipofectamine methods following the procedure recommended by the manufacturer (Gibco-BRL). Twenty-four hours after transfection, 200 g/ml of hygromycin was added. Forty-eight hours after transfection, the cells were trypsinized and selected in the 200 g/ml of hygromycin for another 24 or 48 h. Cells were prepared for cytometry as described (Ausubel et al., 1989) . Briefly, the hygromycin resistant cells (about 0.5 ϫ 10 6 ) cells were pelleted and resuspended into 0.1 ml of PBS with 1% of glucose and then fixed by the addition of 1 ml of 70% ethanol and incubated at 4°C for at least 15 hours. The fixed cells were pelleted then resuspended into 0.1 ml of PBS with 1% glucose and then treated with 0.5 ml of PBS containing 1% glucose, RNase A (50 U/ml), and propidium iodide (PI) (50 g/ml) for at least 60 min before flow cytometric analysis with the Cellquest program (Becton Dickinson Immunocytometry Systems).
Polymerase chain reaction (PCR)
PCR reactions consisted of 50 mM KCl, 10 mM TrisHCl (pH 9.0), 0.1% Triton X-100, 1.5 mM MgCl 2 , 20 pmol of each primer, template plasmid DNA, 0.25 mM dNTP, and 2.5 U of Taq polymerase. The reaction was carried out in a total volume of 50 l. The first cycle was performed at 94°C 3 min, 72°C 2 min, 50°C 1 min 30 s, followed by 30 cycles of 94°C 45 s, 72°C 2 min, and 55°C 1 min. The last cycle extension time at 72°C was 10 min.
